.png)
Our experts in pharmaceutical development have done it: take a concept and deliver a FDA/EMA approved small molecule. Through experience we know the right kind of questions to ask, when to ask them and how to define success.
_________________________
_____________________________
.png)
In the world of excessive pharmaceutical consulting, you need to find experts who have actually done it right. Experts who have been in the thick of it, have developed drugs, talked to Regulators and raised money.
Dr. Robert Huizinga co-founded Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), and developed the rare disease global clinical program of voclosporin since its inception through to FDA and EMA approvals. This included presenting to the FDA, EMA, MHRA, PMDA, BfArM, and Health Canada. In addition, he created a preclinical program for new molecule development and created the Experimental, Translational, Pharmacology & Pharmacometrics and Process Development teams. During his tenure, he increased US and Canadian shareholder value from <$10 million to a peak $4.2 Billion over 10 years. He has raised over $500 million USD in the public markets and spearheaded international healthcare partnership/out-licensing deals including China, Korea, USA, Japan and Canada.
Dr. Huizinga has been involved in numerous trials in immunosuppression, has numerous articles in leading medical journals in the areas of pharmacology, immunology, transplantation, and autoimmune diseases, and has 4 granted patents.
.png)
.png)
.png)
